Literature DB >> 20814447

How HIV treatment could result in effective prevention.

Kartik K Venkatesh1, Mark N Lurie, Kenneth H Mayer.   

Abstract

As the number of HIV infections continues to surpass treatment capacity, new HIV prevention strategies are imperative. Beyond individual clinical benefits, by rendering an individual less infectious, expanding access to highly active antiretroviral therapy (HAART) could also have a larger public health impact of curbing new HIV infections. Recent guidelines have moved towards initiating HAART at higher CD4 cell counts, thus increasing the number of individuals in need of treatment. A new treatment strategy is wanting that can simultaneously curb the epidemic and provide necessary treatment to those most in need. A recent debate has centered on whether an expansion of free and universal treatment, regardless of CD4 cell count, could be a means of HIV prevention. In light of the growing access to HAART in resource-limited settings and increasing evidence suggesting the clinical and prevention benefits of initiating treatment at higher CD4 cell counts, it is conceivable that, in the future, HAART will be an integral part of both individual-level clinical treatment programs as well as public health-based HIV prevention interventions.

Entities:  

Year:  2010        PMID: 20814447      PMCID: PMC2929800          DOI: 10.2217/fvl.10.38

Source DB:  PubMed          Journal:  Future Virol        ISSN: 1746-0794            Impact factor:   1.831


  92 in total

Review 1.  Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

Authors:  J X Velasco-Hernandez; H B Gershengorn; S M Blower
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

2.  Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection.

Authors:  Hendrik Streeck; Heiko Jessen; Galit Alter; Nickolas Teigen; Mike T Waring; Arne Jessen; Ingrid Stahmer; Jan van Lunzen; Mathias Lichterfeld; Xiaojiang Gao; Todd M Allen; Mary Carrington; Bruce D Walker; Juergen K Rockstroh; Marcus Altfeld
Journal:  J Infect Dis       Date:  2006-08-15       Impact factor: 5.226

3.  Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda.

Authors:  Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin
Journal:  AIDS       Date:  2006-01-02       Impact factor: 4.177

4.  Can antiretroviral therapy eliminate HIV transmission?

Authors:  Kevin M De Cock; Charles F Gilks; Ying-Ru Lo; Teguest Guerma
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

5.  Risk of HIV transmission in discordant couples.

Authors:  Geoffrey P Garnett; Brian Gazzard
Journal:  Lancet       Date:  2008-07-26       Impact factor: 79.321

6.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Authors:  Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

7.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.

Authors:  Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn
Journal:  J Infect Dis       Date:  2005-03-30       Impact factor: 5.226

8.  Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi.

Authors:  Anthony D Harries; Erik J Schouten; Simon D Makombe; Edwin Libamba; Henry N Neufville; Eliab Some; Godfrey Kadewere; Douglas Lungu
Journal:  Bull World Health Organ       Date:  2007-02       Impact factor: 9.408

9.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

10.  Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.

Authors:  N Kumarasamy; Kartik K Venkatesh; Anitha J Cecelia; Bella Devaleenal; Andrew R Lai; Suneeta Saghayam; P Balakrishnan; Toku Yepthomi; S Poongulali; Timothy P Flanigan; Suniti Solomon; Kenneth H Mayer
Journal:  AIDS Patient Care STDS       Date:  2008-04       Impact factor: 5.078

View more
  4 in total

Review 1.  Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world.

Authors:  Kartik K Venkatesh; Timothy P Flanigan; Kenneth H Mayer
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

2.  Antiretroviral Treatment Adherence: Knowledge and Experiences among Adolescents and Young Adults in Soweto, South Africa.

Authors:  Stefanie Hornschuh; Janan Janine Dietrich; Celokuhle Tshabalala; Fatima Laher
Journal:  AIDS Res Treat       Date:  2017-03-20

Review 3.  The Cost-Effectiveness of HIV/STI Prevention in High-Income Countries with Concentrated Epidemic Settings: A Scoping Review.

Authors:  Palmo Brunner; Karma Brunner; Daniel Kübler
Journal:  AIDS Behav       Date:  2022-01-15

4.  Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.

Authors:  Ingrid V Bassett; Darshini Govindasamy; Alison S Erlwanger; Emily P Hyle; Katharina Kranzer; Nienke van Schaik; Farzad Noubary; A David Paltiel; Robin Wood; Rochelle P Walensky; Elena Losina; Linda-Gail Bekker; Kenneth A Freedberg
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.